Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC -4.90%58 Days Inventory is 104.60 as of Mar. 2026, which is 59% above its 10-year median of 65.71. GuruFocus rates NSE:SOTAC with a GF Score™ of 58/100 and a GF Value™ of ₹140.86 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 67.5% on this metric.
The historical rank and industry rank for Sotac Pharmaceuticals's Days Inventory or its related term are showing as below:
NSE:SOTAC'
s Days Inventory Range Over the Past 10 Years
Min: 32.77 Med: 65.71 Max: 133.92
Current: 125.56
During the past 7 years, Sotac Pharmaceuticals's highest Days Inventory was 133.92. The lowest was 32.77. And the median was 65.71.
NSE:SOTAC's Days Inventory is ranked better than 67.5% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs NSE:SOTAC: 125.56
Sotac Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (124.14) to Mar. 2026 (104.60).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sotac Pharmaceuticals's Inventory Turnover for the
six
months ended in Mar. 2026 was 1.74.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sotac Pharmaceuticals's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.39.
Sotac Pharmaceuticals (NSE:SOTAC) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sotac Pharmaceuticals's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sotac Pharmaceuticals's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sotac Pharmaceuticals Days Inventory Related Terms
Sotac Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a Days Inventory of 104.60 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sotac Pharmaceuticals and its competitors. This is 59% above median its historical median of 65.71. Over the past decade, Sotac Pharmaceuticals' Days Inventory has ranged from 32.77 to 133.92. According to the industry distribution chart, Sotac Pharmaceuticals ranks #300 out of 923 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Sotac Pharmaceuticals' Days Inventory too high?
Sotac Pharmaceuticals' current Days Inventory of 104.60 is 59% above median its 10-year median of 65.71. Over the past 10 years, this metric has ranged from a low of 32.77 to a high of 133.92. The Drug Manufacturers industry median Days Inventory is 164.38. Sotac Pharmaceuticals' value of 104.60 is 36.4% below this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #300 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #300 out of 923 companies for Days Inventory. This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median Days Inventory is 164.38. Sotac Pharmaceuticals' value of 104.60 is 36.4% below this benchmark. Historically, Sotac Pharmaceuticals' own Days Inventory has ranged from 32.77 to 133.92 over the past decade. While the company's 10-year median is 65.71 vs. the industry median of 164.38, Sotac Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current Days Inventory of 104.60 is 36.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current Days Inventory is 104.60, which is 59% above median its own 10-year median of 65.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹140.86, compared to a current price of ₹95.10 — trading 32.5% below its estimated fair value. The current Days Inventory is 104.60, which is 59% above median its 10-year median of 65.71 and 36.4% below the Drug Manufacturers industry median of 164.38. Sotac Pharmaceuticals' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Days Inventory is 104.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹95.10 is trading 32.5% below its estimated GF Value™ of ₹140.86.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
Days Inventory: 104.60 (59% above median its 10-year median of 65.71)
GF Value™: ₹140.86 vs. price of ₹95.10 (32.5% below fair value)
Industry Position: 36.4% below the Drug Manufacturers median (#300 of 923)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
58GF Score
Get the complete analysis for NSE:SOTAC
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
